Top Stocks
Top Gainers
Latest News — DRREDDY
News
Dr Reddys Share Price Live Updates: Dr. Reddys stock price update
News
Dr Reddys Share Price Live Updates: Current performance of Dr. Reddys
News
Dr Reddys Share Price Live Updates: Dr. Reddys reports a drop in stock price
News
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories records a closing price of Rs 1178.0
News
Dr Reddys Share Price Live Updates: Dr. Reddys Achieves Significant Price Movement
News
Dr Reddys Share Price Live Updates: Dr. Reddys Price and Volume Overview
News
Dr Reddys Share Price Live Updates: Dr. Reddys Trading Volume Insights
News
Dr Reddys Share Price Live Updates: Dr. Reddys market performance update
News
Dr Reddy's Q1 Review: Brokerages Cut Targets After Q1 Miss; Weak US Business, Semaglutide Hit Key Triggers — Morgan Stanley, BofA and Citi cut target prices on Dr Reddy's after a weak Q1. Here's what they said about semaglutide, margins and H2 recovery.
News
Stock Market Crash News Today Live Updates: Nifty Slumps Below 23,900; Sensex Falls Over 400 Points; Dr. Reddy's, HPCL Fall Up To 5% After Q1 Results — Nifty Pharma fell 0.8%, while Nifty Realty declined 0.7%. Nifty IT, Private Bank and Oil & Gas also traded lower.
News
Dr Reddy's Shares Fall Nearly 7% After Weaker-Than-Expected Q1 Results — Dr Reddy's shares fell upto 6.92%, later recovering slightly to dip by 2.82% at Rs 1,149.50 apiece.
News
Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices — Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher solvent and freight costs due to the Middle East conflict further squeezed EBITDA margins.
News
Dr Reddy’s shares crash 9% after weak Q1 results. Here’s why these 3 brokerages are bearish — Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher solvent and freight costs due to the Middle East conflict further squeezed EBITDA margins.
News
Dr. Reddy's Gets Double Blow After Q1: Rating Downgrade, Target Price Cut By Dolat Capital — Here's Why — The quarter included a provision of Rs 240 crore towards inventory and other associated costs related to Semaglutide API.
News
Stocks To Watch Today: HPCL, IndusInd Bank, Dr. Reddy's, NTPC Green, Waaree Renewable & More — Here's a look at stocks that are likely to be in focus during the trading session on Thursday.
Want real-time updates and interactive TradingView charts? Register for a free account.
Get Live Access — Free